A5057100466- Breast Cancer Treatment Studies
- Cancer Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Brain Metastases and Treatment
- Cancer Treatment and Pharmacology
- Radiomics and Machine Learning in Medical Imaging
- MRI in cancer diagnosis
- Glioma Diagnosis and Treatment
- Estrogen and related hormone effects
Institut Claudius Regaud
2021-2024
Institut universitaire du cancer de Toulouse Oncopole
2020
Local ablative treatment (LAT) is increasingly combined with systemic therapy in oligometastatic breast cancer (OMBC), without a high-level evidence to support this strategy. We evaluated the addition of LAT terms progression-free survival (PFS) and overall (OS). Secondary endpoints were local control (LC) toxicity. sought identify prognostic factors associated longer OS PFS.
e13054 Background: In recent years, thanks to large, consecutive and retrospective series, knowledge of oligometastatic breast cancer (OMBC) has improved. However, the underlying pathophysiological mechanisms patterns progression OMBC remain largely unknown. The aim this study is determine whether limited capacity metastasize persisted in patients receiving first-line systemic treatment at stage. To obtain a biologically homogeneous cohort, analysis focused on hormone receptor positive (HR+)...
1058 Background: Some recommend curative treatment for oligometastatic breast cancer (OMBC). To date, no randomized clinical trial has demonstrated the benefits of such a strategy. We present largest retrospective series patients treated consecutively ER and/or PR positive (HR+) OMBC in single institution. The objective was to describe and biological characteristics prognostic factors HR+ OMBC. Methods: retrospectively reviewed all from 2014 2018 at our institution synchronous or...
Abstract Background: In order to determine the optimal treatment strategy for oligometastatic breast cancer (OMBC), effective and safe treatments metastatic sites sensitive specific imaging techniques are needed. But it is also essential know incidence of its clinical biological characteristics [1]. Efficient therapeutic tools exist, but knowledge incidence, OMBC scarce. This partly due lack publications describing these data on recent, consecutive, unselected series OMBC. Methods: we...
Abstract Purpose: Data about incidence, biological and clinical characteristics of oligometastatic breast cancer (OMBC) are scarce. However, these data essential in determining optimal treatment strategy. Gaining knowledge elements means observing describing large, recent, consecutive series OMBC their natural history. Methods: We collected retrospectively at our institution from 998 patients diagnosed treated with synchronous or metachronous metastatic (MBC) between January 2014 December...
Abstract BACKGROUND Due to the risk of pseudo-progression, evaluating response such combined treatment with anti-PDL1 immunotherapy and hypofractionated stereotactic radiotherapy (hFSRT) in patients recurrent glioblastoma (GBM) is difficult even iRANO criteria. We aim analyze multi-modal MRI radiomic features GBM included phase I STERIMGLI (NCT02866747) clinical trial. MATERIAL AND METHODS In trial STERIMGLI, six received hFSRT 24 Gy 3 fractions 8 prescribed 80% covering isodose combination...